ReNerve

ReNerve FCF Yield

Free Cash Flow Yield of ReNerve (RNV.AX) as of Oct 18, 2026.

FCF Yield

0.00

Last updated:

Free Cash Flow Yield of ReNerve is 2026 0.00 . Free Cash Flow Yield of ReNerve was 2025 -27.64 % . It decreases by % higher compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ReNerve Stock analysis

What does ReNerve do? ReNerve Ltd is an Australian company operating in the Health Care sector. It develops medical devices for peripheral nerve repair and replacement, focusing on tissue-based products that accelerate regeneration and prevent scarring. The company's products include NervAlign Nerve Cuff, designed to protect repaired nerves during surgery, and NervAlign Nerve Graft, which allows nerve repair without harvesting the sural nerve. NervAlign Bionic Nerve is under development, combining polymer technology to stimulate nerve injury sites. The company's IPO occurred on November 26, 2024. Its website is https://renerve.com.au/ ReNerve is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ReNerve stock

On Eulerpool you can find the complete historical development of Free Cash Flow Yield ReNerve since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's ReNerve with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — ReNerve

All Key Metrics — ReNerve